Abstract: The present invention provides, without use of a surfactant, an oil-in-water emulsion composition and cosmetics having fresh and smooth feeling without powderiness in use, and having excellent emulsion stability by preparing a Pickering emulsion using a spherical polylactic acid powder. An oil-in-water emulsion composition is obtained as a composition containing (a) a spherical polylactic acid powder having an average particle size of from 0.5 to 1.5 ?m, wherein 90% by volume or more of the whole particles of the powder have a particle size of 3 ?m or less, (b) an oil phase component, and (c) an aqueous phase component, and containing substantially no surfactant. Desired cosmetics are obtained by using the oil-in-water emulsion composition.

Abstract: The present invention relates to antiperspirant cosmetic agents in the form of an O/W emulsion, which include a combination of an antiperspirant compound with a cross-linked silicone polymer in a weight ratio of 3:1 to 12:1. The previously mentioned combination leads to an improved antiperspirant effect of the O/W emulsions and to improved cosmetic properties, particularly reduced tackiness and textile soiling. The present invention also relates to a method for preventing and/or reducing the perspiration of the body by using the O/W emulsions and the use of at least one cross-linked silicone polymer in O/W emulsions to improve the antiperspirant effect of said emulsions.

Abstract: A hair care composition is provided imparting enhanced shine to hair comprising a) from about 0.1% to about 10.0% by weight of the composition of a non-volatile polysiloxane fluid; b) from about 0.02% to about 5.0% by weight of the composition of a surfactant mixture comprising a shining surfactant and a secondary surfactant, wherein the shining surfactant is a polyether siloxane copolymer; c) from about 0.003% to about 0.6% by weight of the composition of a rheology modifier comprising an acrylic acid/Vinyl ester copolymer; and d) a carrier suitable for the application to hair wherein the composition is free of ethanol and the viscosity s less than 7 Pa*s. Further a method is provided comprising spraying the composition with a particle size in the range of from about 0.01 ?m to about 10 ?m, wherein the resulting film is in the range of from about 100 nm to about 500 nm after drying.

Abstract: A method is provided which provides shine to hair comprising spraying a leave-on composition to hair with a particle size in the range of from about 0.01 ?m to about 10 ?m, wherein the resulting film at the dried hair is in the range of from about 100 nm to about 500 nm and more than 25% of the hair fibers are covered. The oil-in water polysiloxane emulsion shows a viscosity of less than 7 Pa*s and a pH value from about 4 to about 8. The emulsion comprises about 0.1% to about 10% by weight of a non-volatile polysiloxane fluid and from about 0.003% to about 0.6% by weight of a rheology modifier, wherein less than 0.015 g of the non-volatile polysiloxane fluid are applied per gram hair.

Abstract: The present invention relates to a nail care system containing (1) at least one composition containing at least one adhesive agent, at least one primary film former and at least one plasticizer; and (2) an applicator.

Abstract: Anhydrous device in the form of a closed shell containing a fatty phase, the shell and the fatty phase constituting the necessary ingredients and in an amount adequate for the extemporaneous preparation of a single-use cosmetic emulsion, solely by adding water.

Abstract: A preparation is provided for enhancement of imaging of fingerprints and palm prints acquired using a Live Scan device. The preparation is solid at room temperature, even in hot climates, and can be consistently applied. The preparation is a mixture of: 20%-70% beeswax; 1.0%-50% squalane; 1.0%-10% jojoba oil; and 0.1%-5.0% tea tree oil. The mixture can be advantageously molded into a shape that facilitates application, such as the shape of a deodorant stick or lip balm. Preferably, the preparation consists of: 60% beeswax; 30% squalane; 9% jojoba oil; and 1% tea tree oil. The preparation moisturizes skin to facilitate higher quality images on AFIS or IAFIS Live Scanners, and includes an antimicrobial to maximize sanitary conditions, includes no alcohol to be safe to use around a breathalyzer, is non-toxic for use in jails and mental institutions, and will not stain clothing.

Abstract: The present invention relates to a skin care composition comprising an extract of Bursera simaruba seeds and a cosmetically acceptable topical carrier. Such composition is useful for improving skin barrier function and moisturization as well as improving signs of skin aging.

Abstract: A pharmaceutical composition is provided for transmucosal administration of an active lipophilic compound through the oral mucosa comprising a lipophilic active compound, a polymeric matrix formed by two or more water-soluble polymers and a rapid dissolution agent. At least one of the water-soluble polymers is an amphiphilic polymer and at least one is either a hydrophilic polymer or an amphiphilic polymer with a hydrophobic-hydrophilic balance different from the first amphiphilic polymer. In addition, the polymeric matrix is not crosslinked and no covalent interaction occurs between the two or more polymers and between the polymers and the lipophilic active compound, which is interwoven with the aforesaid polymeric matrix.

Abstract: In one aspect, the invention provides injectable compositions that comprise a suitable hydrophilic polymer (e.g., a suitable polysaccharide) and water, as well as other optional components. In various embodiments, the composition may be provided in a suitable container, for example, in a pre-loaded syringe. In another aspect, methods of performing medical procedures in a tract of a body are provided. In yet another aspect, the invention provides systems for performing medical procedures in a tract of a body.

Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbiocidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.

Abstract: A gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for formulating for once daily or twice daily administration. Further provided is a method of treating a disorder by administering to a patient in need thereof, a gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The opioid is either in slow release form or in immediate release form.

Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.

Abstract: The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

Abstract: A stable liposomal formulation for ocular delivery of an alpha 2 adrenergic agonist. The formulation contains a liposome that includes a lipid bilayer including a phosphatidylcholine. An alpha 2 adrenergic agonist is encapsulated in the liposome.

Abstract: Provided are a novel imidazole compound which has a high stability of the compound itself; and a novel imidazole compound which is useful as a membrane-constituting lipid of liposomes. Disclosed are a compound represented by the following General Formula (1), and a liposome containing the same compound. In the formula, Z is an imidazolyl group which may be substituted, L1 is an alkylene group having 1 to 4 carbon atoms which may be substituted, X is an oxygen atom or a nitrogen-containing substituent, n is an integer of 2 to 4, m is an integer of 1 to 20, L2 is a divalent linking group having 1 to 6 carbon atoms, Y is a nitrogen-containing group, R1 and R2 are a hydrogen group or an alkyl group having 1 to 6 carbon atoms, R3 is a hydrogen atom or a substituent, and R4 and R5 are an alkyl group having 1 to 40 carbon atoms.

Abstract: Embodiments of the present disclosure include particles, methods of making particles, methods of delivering an active agent using the particle, and the like.

Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.

Abstract: A fiber fluidic system may be used to produce particles (e.g., NPs and/or microparticles). The fiber fluidic system may include a cylinder with a plurality of elongated fibers oriented along a length of the cylinder. The cylinder may have a first opening at or near a first end of the cylinder and a second opening downstream of the first opening. A constrained phase fluid may be provided through the first opening and a free phase fluid may be provided through the second opening to produce particles (e.g., NPs and/or microparticles) through a second end of the cylinder. The fiber fluidic system may be used to continuously produce the particles at high throughput.

Abstract: A solid pharmaceutical composition comprising a solid dispersion of a BCS Class II drug in a solid carrier/hydrophilic carrier; and a pH modifier. The solid carrier/hydrophilic carrier has a melting point of between about 40° C. to about 60° C. and an HLB value of between about 10 and about 18. The BCS Class II drug may be telmisartan.

Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.

Abstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.

Abstract: The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.

Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Abstract: Disclosed herein are a novel polymer, a thermosensitive carrier prepared using the same and use thereof. The novel polymer is essentially composed of a PEO-PPO-PEO block copolymer and silane.

Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Abstract: The present invention relates to solid oral dosage forms of carvedilol phosphate. More specifically, the present invention relates to extended release compositions of carvedilol phosphate and process for their preparation.

Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.

Abstract: Pharmaceutical formulations, preferably in the form of softgel capsules or hard-shell capsules, exhibit extended release through the use of a coating comprising a water-insoluble polymer and a pH-independent pore former. Extended release from softgel capsules and hard-shell capsules can be achieved without the use of lipid-based semi-solid or solid materials.

Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.

Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.

Abstract: The present invention relates to compositions comprising a biopolymer-encapsulated glycosyltransferase inhibitor and methods for treating and reducing a symptom of atherosclerosis or cardiac hypertrophy and/or diabetes using said compositions.

Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.

Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Abstract: Provided herein is a method for producing triblock copolymer-coated metallic nanoparticle seeds which increases the size and shape homogeneity of the triblock copolymer-coated metallic nanoparticle seeds. Also provided is a quantity of triblock copolymer-coated metallic nanoparticle seeds. Also provided herein is a method for producing triblock copolymer-coated metallic nanoparticles which increases the size and shape homogeneity of the triblock copolymer-coated metallic nanoparticles. Also provided is a quantity of triblock copolymer-coated metallic nanoparticles. Further provided herein is a method for producing modified metallic nanoparticles which increases the size and shape homogeneity of the modified metallic nanoparticles. Also provided is a quantity of modified metallic nanoparticles.

Abstract: The invention provides nanoparticle-stabilized nanocapsules, and methods of their preparation and use in delivery of therapeutics, such as nucleic acids. Various embodiments disclosed relate to a nanoparticle-stabilized nanocapsule. Various embodiments disclosed relate to nanoparticle-stabilized nanocapsules for nucleic acid delivery into cells. Various embodiments provide methods of using the nanocapsule for in vivo delivery of the nucleic acid materials.

Abstract: The present invention relates to disintegratable core/shell silica particles encapsulating a bioactive macromolecule or bioactive macromolecule cluster in an active conformation, a method for producing the same, and uses thereof.

Abstract: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.

Abstract: The present invention relates to electrospun fibers comprising i) a hydrophilic polymer that is soluble in a first solvent, ii) a bioadhesive substance that is slightly soluble in said first solvent, iii) optionally, a drug substance.

Abstract: A transdermal absorption sheet and a manufacturing method for the transdermal absorption sheet includes a laminating step of forming a multilayer film with a viscosity difference by forming, on a support, a lower layer containing a first transdermal absorption material and an upper layer containing a drug and a second transdermal absorption material and having a lower viscosity than the lower layer, a filling step of filling needle-like recessed portions corresponding to inverted needle-like protruding portions with a solution of the transdermal absorption material by pressing a mold in which the needle-like recessed portions are arranged in a two-dimensional array, against a surface of the multilayer film supported by the support to allow the multilayer film to flow, a solidifying step of solidifying the multilayer film with the mold pressed against the surface of the multilayer film, and a peeling-off step of peeling the solidified multilayer film from the mold.

Abstract: A drug-containing microcapillary film having: (a) a matrix comprising a polymer having a glass transition temperature less than 190° C.; wherein the matrix has a thickness from 5 to 2000 microns; (b) channels disposed in parallel in the matrix, wherein the channels are separated from each other by at least 1 micron, and wherein total cross-sectional area of the channels is from 5 to 70% of total cross-sectional area of the film; and (c) at least one drug disposed in the matrix and/or in the channels.

Abstract: Methods of improving glucose tolerance in a mammal, improving hair growth and re-growth in a mammal and improving the bio-availability of resveratrol in a mammal by providing a mammal in need of 10 mg to 500 mg per kilogram of body weight of mammal of a resveratrol-arginine conjugate.

Abstract: A compound of formula (I) R-L-CO—X??(I) wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO wherein L comprises at least one heteroatom in the backbone of the linking group; and X is an electron withdrawing group or a salt thereof for use in the treatment of skin cancer such as basal cell carcinoma.

Abstract: The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.

Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.

Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours.

Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.

Abstract: The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment; the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive charge. The positive charge and enhancers used in the formula allow for increased penetration of the active ingredient through skin and skin appendages. The positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle.

Abstract: The invention relates to a drug sustained-release composition, particularly a sustained-release composition comprising metoprolol and preparation method thereof. The invention also relates to a combination product comprising a sustained-release composition comprising metoprolol and a pharmaceutical composition comprising hydrochlorothiazide. The sustained-release composition comprising metoprolol according to the invention eliminates the phenomena of delayed release of such sustained-release compositions in the prior art, has a better drug release curve, and also have the advantages such as simple formula, easy operation, stable quality, strong controllability, and good reproducibility, and therefore have good application prospects.